PubMed Journals Articles About "Late John Mendlein Joins Reinventing Biotech Lineup April" RSS

19:43 EDT 3rd July 2015 | BioPortfolio

Late John Mendlein Joins Reinventing Biotech Lineup April PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Late John Mendlein Joins Reinventing Biotech Lineup April articles that have been published worldwide.

More Information about "Late John Mendlein Joins Reinventing Biotech Lineup April" on BioPortfolio

We have published hundreds of Late John Mendlein Joins Reinventing Biotech Lineup April news stories on BioPortfolio along with dozens of Late John Mendlein Joins Reinventing Biotech Lineup April Clinical Trials and PubMed Articles about Late John Mendlein Joins Reinventing Biotech Lineup April for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Late John Mendlein Joins Reinventing Biotech Lineup April Companies in our database. You can also find out about relevant Late John Mendlein Joins Reinventing Biotech Lineup April Drugs and Medications on this site too.

Showing "Late John Mendlein Joins Reinventing Biotech Lineup April" PubMed Articles 1–25 of 3,400+

Extremely Relevant

Eyewitness Identification Across the Life Span: A Meta-Analysis of Age Differences.

Lineup identifications are often a critical component of criminal investigations. Over the past 35 years, researchers have been conducting empirical studies to assess the impact of witness age on identification accuracy. A previous meta-analysis indicated that children are less likely than adults to correctly reject a lineup that does not contain the culprit, but children 5 years and older are as likely as adults to make a correct identification if the culprit is in the lineup (Pozzulo & Lindsay, 1998). We ...

Relevant

Reinventing tech transfer.

Erratum: Reinventing tech transfer.

2016 Call for Conference Proposals What Is the Purpose of Health Promotion? Money, Health, or More? Do We Need to Produce a Huge ROI, or Do We Need to Engage People, Improve Health and Better Serve the Organization or Community's Broader Goals?26th Annual Art & Science of Health Promotion Conference, April 25-April 29, 2016 | Hilton Orlando Lake Buena Vista | Orlando, FloridaCore Conference: April

Pfizer joins PD-L1 pursuit.

Third-quarter biotech job picture.

Biotech on the bounce in 3Q14.

First-quarter biotech job picture.

Bridging tech and biotech.

Psychosocial cancer research - late career perspectives: the International Psycho-Oncology Society 2014 Sutherland Award lecture.

This paper consists of reflections in relation to how follow-up is organized in the growing population of cancer survivors. It also includes focus on late effects in cancer patients. The paper also highlights research contributions in the area of depression in cancer patients and discusses these findings in relation to the daily clinical practice. Parts of this paper were a lecture given as a humble response to the Arthur M. Sutherland Award 2014. Copyright © 2015 John Wiley & Sons, Ltd.

Warren joins lawmakers proposing new ideas for science funding.

Identification of the sAPRIL Binding Peptide and Its Growth Inhibition Effects in the Colorectal Cancer Cells.

A proliferation-inducing ligand (APRIL) is a member of the tumor necrosis factor (TNF) super family. It binds to its specific receptors and is involved in multiple processes during tumorigenesis and tumor cells proliferation. High levels of APRIL expression are closely correlated to the growth, metastasis, and 5-FU drug resistance of colorectal cancer. The aim of this study was to identify a specific APRIL binding peptide (BP) able to block APRIL activity that could be used as a potential treatment for colo...

Fourth-quarter biotech job picture.

Fresh from the biotech pipeline-2014.

2014-the biotech bull rages on.

Biotech continues to soar in 1Q15.

Continuous Processing for Production of Biotech Therapeutics.

John H. Laragh MD: The Man.

John has been variously described as an inspiration, mentor, teacher, friend (fiend-a typo?), charming, warm, enthusiastic, visionary scientist, pioneer, innovator, egalitarian, and golfer. At other times he was called street fighter, competitor, and some unprintables. I believe he was all of these, and more.

Erratum: Public biotech 2013-the numbers.

Big-cap buying bonanza trickles down to small biotech.

NewsCAP: Nebraska joins 19 other states in granting full practice authority to NPs.

Influence of Seeding Ratio, Planting Date, and Termination Date on Rye-Hairy Vetch Cover Crop Mixture Performance under Organic Management.

Cover crop benefits include nitrogen accumulation and retention, weed suppression, organic matter maintenance, and reduced erosion. Organic farmers need region-specific information on winter cover crop performance to effectively integrate cover crops into their crop rotations. Our research objective was to compare cover crop seeding mixtures, planting dates, and termination dates on performance of rye (Secale cereale L.) and hairy vetch (Vicia villosa Roth) monocultures and mixtures in the maritime Pacific ...

CRISPR germline editing reverberates through biotech industry.

Kernel Compositions of Glyphosate-Tolerant and Corn Rootworm-Protected MON 88017 Sweet Corn and Insect-Protected MON 89034 Sweet Corn Are Equivalent to That of Conventional Sweet Corn (Zea mays).

Monsanto Co. has developed two sweet corn hybrids, MON 88017 and MON 89034, that contain biotechnology-derived (biotech) traits designed to enhance sustainability and improve agronomic practices. MON 88017 confers benefits of glyphosate tolerance and protection against corn rootworm. MON 89034 provides protection against European corn borer and other lepidopteran insect pests. The purpose of this assessment was to compare the kernel compositions of MON 88017 and MON 89034 sweet corn with that of a conventio...

Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients.

We have previously shown that the tumor necrosis factor family member a proliferation-inducing ligand (APRIL) enhances intestinal tumor growth in various preclinical tumor models. Here, we have investigated whether APRIL serum levels at time of surgery predict survival in a large cohort of colorectal cancer (CRC) patients. We measured circulating APRIL levels in a cohort of CRC patients (n=432) using a novel validated monoclonal APRIL antibody (hAPRIL.133) in an enzyme-linked immunosorbent assay (ELISA) set...



Advertisement
 
Advertisement
 

PubMed Database Quicklinks